Midora (Amisulpride)

Amisulpride is a selective antagonist of dopamine D2 and D3 receptors. At low doses it blocks presynaptic dopamine autoreceptors, increasing dopamine release, which can improve depressive symptoms. At higher doses it blocks postsynaptic receptors, reducing dopaminergic transmission in brain regions that mediate psychosis, thereby alleviating hallucinations, delusions, and other psychotic symptoms.

The appropriate dose of Midora is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Dosage may be adjusted according to therapeutic goals and any renal or hepatic considerations. Patients should follow the prescribing information and never change the dose without consulting their healthcare professional.

The safety of amisulpride in pregnancy and lactation has not been definitively established, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefits outweigh the possible risks, and it must be decided by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Midora product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and assists with any required import documentation.

Compared with many typical antipsychotics, amisulpride has a more selective dopamine D2/D3 antagonism and a lower propensity for extrapyramidal side effects at therapeutic doses. Unlike some atypical agents, it does not significantly block serotonin receptors, which may result in a different side‑effect profile, such as higher rates of hyperprolactinemia. Choice of therapy depends on individual patient factors, efficacy, tolerability and clinician experience.

Midora should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date. If the tablets become damaged or discolored, discard them according to local regulations.

Midora is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed. Consistency in the timing of each dose helps maintain stable drug levels and optimizes therapeutic effect.

The most serious risks include the development of tardive dyskinesia, neuroleptic malignant syndrome, severe hyperprolactinemia, agranulocytosis, and cardiac QT interval prolongation, which can lead to life‑threatening arrhythmias. Patients should be monitored regularly for early signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Midora is contraindicated in individuals with known hypersensitivity to amisulpride or any of the tablet excipients. It should be avoided in patients with a history of severe cardiac conduction disorders, uncontrolled QT prolongation, or those currently receiving medications that significantly prolong the QT interval. Caution is also advised for patients with renal impairment, and it is generally not recommended for children or adolescents unless specifically prescribed by a specialist.